BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36456112)

  • 1. 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1.
    Schöder H
    J Nucl Med; 2022 Dec; 63(12):13N-18N. PubMed ID: 36456112
    [No Abstract]   [Full Text] [Related]  

  • 2. 2021 SNMMI Highlights Lecture: Oncology and Therapy, Part 2.
    Schöder H
    J Nucl Med; 2021 Nov; 62(11):11N-16N. PubMed ID: 34725234
    [No Abstract]   [Full Text] [Related]  

  • 3. 2021 SNMMI Highlights Lecture: Oncology and Therapy, Part 1.
    Schöder H
    J Nucl Med; 2021 Oct; 62(10):9N-15N. PubMed ID: 34599016
    [No Abstract]   [Full Text] [Related]  

  • 4. 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2.
    Schöder H
    J Nucl Med; 2023 Jan; 64(1):2-7. PubMed ID: 36599474
    [No Abstract]   [Full Text] [Related]  

  • 5. 2022 SNMMI Highlights Lecture: Neuroscience.
    Price J
    J Nucl Med; 2022 Nov; 63(11):15N-22N. PubMed ID: 36319112
    [No Abstract]   [Full Text] [Related]  

  • 6. 2021 SNMMI Highlights Lecture: Cardiovascular Track.
    Dorbala S
    J Nucl Med; 2022 Jan; 63(1):11N-16N. PubMed ID: 34980669
    [No Abstract]   [Full Text] [Related]  

  • 7. 2022 SNMMI Highlights Lecture: General Nuclear Medicine.
    Iagaru A
    J Nucl Med; 2023 May; 64(5):671-677. PubMed ID: 37055218
    [No Abstract]   [Full Text] [Related]  

  • 8. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
    Høilund-Carlsen PF
    Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2017 SNMMI Highlights Lecture: Oncology, Part 2.
    Weber W
    J Nucl Med; 2018 Feb; 59(2):9N-15N. PubMed ID: 29419461
    [No Abstract]   [Full Text] [Related]  

  • 11. 2017 SNMMI Highlights Lecture: Oncology.
    Weber W
    J Nucl Med; 2018 Jan; 59(1):7N-13N. PubMed ID: 29295949
    [No Abstract]   [Full Text] [Related]  

  • 12. 2016 SNMMI Highlights Lecture: Oncology, Part 1.
    Weber WA
    J Nucl Med; 2017 Jan; 58(1):9N-15N. PubMed ID: 28062717
    [No Abstract]   [Full Text] [Related]  

  • 13. 2015 SNMMI Highlights Lecture: Oncology, Part II.
    Mahmood U
    J Nucl Med; 2015 Dec; 56(12):9N-16N. PubMed ID: 26626870
    [No Abstract]   [Full Text] [Related]  

  • 14. 2015 SNMMI Highlights Lecture: Oncology, Part I.
    Mahmood U
    J Nucl Med; 2015 Nov; 56(11):9N-16N. PubMed ID: 26526798
    [No Abstract]   [Full Text] [Related]  

  • 15. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can - make nuclear medicine great again".
    Fanti S; Bonfiglioli R; Decristoforo C
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1781-1794. PubMed ID: 29725717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2014 SNMMI highlights lecture: Oncology.
    Mahmood U
    J Nucl Med; 2014 Nov; 55(11):9N-24N. PubMed ID: 25368337
    [No Abstract]   [Full Text] [Related]  

  • 17. Highlights lecture EANM 2015: the search for nuclear medicine's superheroes.
    Buck A; Decristoforo C
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1910-27. PubMed ID: 27229941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies.
    Hong K; Akinwande O; Bodei L; Chamarthy MR; Devlin PM; Elman S; Ganguli S; Kennedy AS; Koo SJ; Ouhib Z; Padia SA; Salem R; Selwyn RG; Yashar CM; Yoo DC; Zaki BI; Hartford AC; Trimmer CK
    Brachytherapy; 2021; 20(3):497-511. PubMed ID: 33824051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Person Profile: Clifford Hudis, MD: The chief executive officer of the American Society of Clinical Oncology previously had an esteemed career as a physician-scientist and executive at the Memorial Sloan Kettering Cancer Center's Breast Medicine Service: The chief executive officer of the American Society of Clinical Oncology previously had an esteemed career as a physician-scientist and executive at the Memorial Sloan Kettering Cancer Center's Breast Medicine Service.
    O'Rourke K
    Cancer; 2022 Mar; 128(5):936-937. PubMed ID: 35147985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.